Rapidly fatal pulmonary fibrosis in a patient with psoriatic arthritis treated with adalimumab

Journal of Rheumatology

Volumn 38, Issue 2, 2011, Pages 398-399

  Cohen, Justine V ^a   Capell, Brian C ^a   Kinniry, Paul A ^a   Epstein, Alan L ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PREDNISONE;

ADULT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FATALITY; HOSPITALIZATION; HUMAN; LETTER; LOW DRUG DOSE; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FATAL OUTCOME; HUMANS; MALE; PULMONARY FIBROSIS;

EID: 79551703612     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100641     Document Type: Letter

References (10)

1. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
2. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005;32:2130-5.
3. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
4. Thavarajah K, Wu P, Rhew EJ, Yeldandi AK, Kamp DW. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med 2009;103:661-9.
5. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004;329:1266.
6. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology 2006;45:1312-3.
7. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum 2006;55:157-9. (Pubitemid 43235143)
8. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 2007;36:172-8.
9. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086-91.
10. Distler JH, Schett G, Gay S, Distler O. The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum 2008;58:2228-35.